The alarming rise of antibiotic-resistant bacteria poses a significant threat to global health. The selective pressure exerted by antibiotic overuse and misuse has rendered previously effective medications powerless against certain bacterial strains. This necessitates the exploration of alternative therapeutic strategies. Phage therapy, the targeted application of bacteriophages (phages), emerges as a promising solution with unique advantages. Phages are naturally occurring viruses that specifically infect and replicate within bacterial cells. This remarkable host specificity offers a significant advantage over broad-spectrum antibiotics, which can disrupt the human microbiome. The therapeutic potential of phages lies in their lytic cycle. Upon encountering a susceptible bacterium, the phage attaches to the cell wall and injects its genetic material. The bacterium’s machinery is then reprogrammed to produce new phages. This rapid replication culminates in host cell lysis (bursting), releasing a fresh batch of phages to infect other bacterial targets. The unique properties of phages make them well-suited for combating antibiotic-resistant bacteria. Unlike antibiotics, which often target specific cellular processes, phages exploit diverse mechanisms for lysis. This complexity makes it challenging for bacteria to develop resistance against phages. Additionally, phages can co-evolve with their bacterial hosts, potentially maintaining their effectiveness over time. Advancements in phage engineering hold further promise for tailoring phages to target specific bacterial strains and overcoming existing resistance mechanisms. Despite its potential, phage therapy faces several hurdles for widespread clinical adoption. Regulatory frameworks for phage therapy are still evolving in many countries. Furthermore, extensive clinical trials are required to establish the safety and efficacy of phage therapy for various bacterial infections. Developing targeted delivery methods to ensure phages reach their intended site of action remains a challenge. Phages offer a compelling approach to combat the growing threat of antibiotic-resistant bacteria. Their natural specificity, co-evolutionary potential, and ability to target resistant strains make them a promising therapeutic avenue. While challenges remain regarding regulations, clinical validation, and delivery methods, further research and development efforts are crucial to integrate phage therapy into mainstream clinical practice.